Lorlatinib Versus Crizotinib in Patients With Advanced ALK-Positive Non-Small Cell Lung Cancer: 5-Year Outcomes From the Phase III CROWN Study - Solomon, BJ; Liu, G; Felip, E (J Clin Oncol, 2024)